The race to explore and harness GenAI in healthcare

This month we have a special feature on GenAI and its impact on pharma – from intelligent content generation to optimising HCP engagement.

In Danny Buckland’s first article, The race to explore and harness GenAI in healthcare, he writes: “GenAI’s reach into healthcare is becoming more comprehensive, with most organisations using some form of AI and actively looking at expanding its digital footprint. It’s been progressing through ever-advancing digital tools and capabilities over the last decade, with the market for GenAI expected to rise from $1.1bn in 2023 to £17.2bn by 2032.” Read more on page 28.

In Danny’s second article, GenAI: Embracing the transformation – with caution, he writes: “Agility in crowded, rapidly-shifting markets is essential and the growing efficacy of large language models and algorithms is a beguiling prospect but, despite the GenAI fervour, key observers feel there is an acute need to prepare organisations to understand what specific tools they need and how to wield them.” Turn to page 34. to find out more.

Also in this month’s issue, we have an article from Dr Gen Li at Phesi, looking at the company’s annual Top Five Most Studied Diseases report. As Dr Li says: “The report, now in its fifth year, looks back at half a decade of ups and downs in the clinical development sector.

It tracks the world’s most studied diseases using contextualised real-world data from more than 300 million patients, and this year’s report was based on 65,892 recruiting clinical trials from across the globe.” Read more on page 16.

It is Rare Disease Day on 28 February and in his article, Patient-centricity in rare disease: accelerating the path to treatment, Chris Moore writes: “More than 300 million people worldwide live with a rare disease, representing up to 5.9% of the global population. With over 6,000 distinct conditions – 72% of which are genetic – the therapeutic landscape is uniquely complex.” Turn to page 18 to find out more.

Our April issue will look at the impact of current weight loss drugs on longer-term behaviour change, the barriers patients face and the role of HCPs and support programmes. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com

I hope you enjoy this issue!

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register